Global Health Q2 FY26: Premium Valuation Tests Investor Patience Despite Solid Operational Performance

The quarter's performance reflects the dual narrative surrounding Global Health: operationally resilient with consistent revenue growth and improving profitability, yet facing investor scepticism over stretched valuations. Trading at a price-to-earnings ratio of 59 times trailing twelve-month earnings and a lofty price-to-book value of 9.96 times, the stock's premium multiple has become a key concern, particularly as the broader hospital sector trades at an average P/E of 69 times.

The company's current "HOLD" rating with a Mojo Score of 54 out of 100 reflects this valuation conundrum. Whilst fundamental quality remains intact with a "GOOD" quality grade and "POSITIVE" financial trend, the "VERY EXPENSIVE" valuation tag and "SIDEWAYS" technical trend have tempered investment enthusiasm. The stock has underperformed its sector by 6.81 percentage points over the past year, delivering 15.83% returns compared to the hospital sector's 22.64% gain.

Financial Performance: Revenue Momentum Masks Margin Pressures

Global Health's Q2 FY26 revenue of ₹1,099.22 crores represents a quarterly high, growing 6.63% sequentially and 14.91% year-on-year. This marks the seventh consecutive quarter of sequential revenue growth, demonstrating the company's ability to scale operations and capture market share in India's expanding healthcare sector. On a half-yearly basis for H1 FY26, the company reported combined revenue of ₹2,130.06 crores, up 17.27% from H1 FY25's ₹1,817.64 crores.

However, margin dynamics present a more nuanced picture. Operating profit before depreciation, interest, and tax (excluding other income) stood at ₹246.93 crores in Q2 FY26, yielding an operating margin of 22.46%. Whilst this represents a sequential decline of 146 basis points from Q1 FY26's 23.92%, it marks an improvement from the year-ago quarter's 23.87%. The margin compression quarter-on-quarter stems primarily from elevated employee costs, which surged to ₹274.33 crores from ₹256.40 crores in Q1 FY26, reflecting a 6.99% sequential increase that outpaced revenue growth.

The profit after tax margin contracted to 14.41% in Q2 FY26 from 15.42% in the preceding quarter, though it remains ahead of the 13.68% recorded in Q2 FY25. On an absolute basis, the company's H1 FY26 consolidated net profit of ₹317.45 crores grew 33.87% compared to H1 FY25, underscoring the underlying earnings momentum despite quarterly fluctuations. This half-yearly performance positions Global Health favourably for FY26, with the company on track to potentially exceed its FY25 full-year net profit of ₹481.00 crores.

Operational Excellence: Capital Efficiency Drives Value Creation

Global Health's operational strength is best exemplified by its return on equity of 15.90%, which places it amongst the top performers in the hospital sector. This metric, indicating the company generates ₹15.90 in profit for every ₹100 of shareholder equity, reflects superior capital efficiency and management quality. The company's ROE has remained consistently above 15% over recent periods, demonstrating sustainable profitability despite the capital-intensive nature of hospital operations.

The company's return on capital employed (ROCE) of 22.53% further reinforces this narrative of operational excellence. With ROCE substantially exceeding the cost of capital and demonstrating an improving trend (latest ROCE at 22.92%), Global Health showcases its ability to deploy capital productively across its hospital network. The five-year compound annual growth rate in operating profit of 33.58% significantly outpaces the 20.50% revenue CAGR, indicating expanding operating leverage as the company scales.

The company's interest coverage ratio, measured by EBIT to interest, averaged 7.76 times over recent periods, providing comfortable headroom for debt servicing. In Q2 FY26, interest costs increased to ₹17.11 crores from ₹13.79 crores in Q1 FY26, marking the highest quarterly interest expense in recent periods. However, given the company's robust operating profit generation and low absolute debt levels, this increase poses no material concern to financial stability.

Working capital management has shown mixed signals. The company witnessed negative working capital changes of ₹99.00 crores in FY25, indicating increased deployment of resources into operations. Current assets stood at ₹1,533.12 crores as of March 2025 against current liabilities of ₹618.82 crores, yielding a healthy current ratio of 2.48, well above the prudent threshold of 1.5 for healthcare companies.

The Valuation Conundrum: Premium Multiple Meets Growth Expectations

Global Health's valuation presents the most significant headwind to fresh investment. Trading at a P/E ratio of 59 times trailing twelve-month earnings, the stock commands a substantial premium despite trading below the hospital sector average of 69 times. The price-to-book value of 9.96 times significantly exceeds most peers, with only Max Healthcare (11.77x) and Narayana Hrudayalaya (10.15x) trading at comparable or higher multiples.

The PEG ratio of 3.20 particularly stands out as a concern. Conventional wisdom suggests a PEG ratio above 2.0 indicates the stock's valuation is not adequately supported by its growth rate. With five-year sales growth of 20.50% and EBIT growth of 33.58%, whilst impressive, these rates do not justify a P/E multiple of 59 times on a PEG basis. The valuation grade has oscillated between "EXPENSIVE" and "VERY EXPENSIVE" since January 2025, with the current "VERY EXPENSIVE" designation persisting since mid-January.

The enterprise value metrics further underscore this premium positioning. An EV/EBITDA multiple of 35.56 times and EV/EBIT of 44.73 times place Global Health amongst the most expensive healthcare stocks in India. For context, the company's EV/Sales ratio of 8.63 times implies investors are paying ₹8.63 for every rupee of revenue, a multiple typically reserved for high-growth technology companies rather than capital-intensive hospital businesses.

Peer Comparison: Leading on Quality, Trailing on Value

Global Health's positioning within the hospital sector reveals a company excelling on fundamental quality metrics but struggling to offer relative value. The company's ROE of 15.90% surpasses most peers, with only Narayana Hrudayalaya (20.13%) and Aster DM Healthcare (17.50%) delivering superior returns on equity. This higher ROE reflects the company's superior capital allocation and operational efficiency, justifying some valuation premium.

However, the company's negative net debt position (debt-to-equity of -0.12) stands out as a unique competitive advantage. Whilst peers like Apollo Hospitals (0.62), Max Healthcare (0.25), Fortis Healthcare (0.22), and Narayana Hrudayalaya (0.22) all carry positive debt loads, Global Health's net cash status provides unmatched financial flexibility. This conservative balance sheet approach reduces financial risk and positions the company favourably for opportunistic expansion or acquisitions.

The price-to-book comparison reveals Global Health trading at 9.96 times book value, substantially higher than Apollo Hospitals (1.21x) and Aster DM Healthcare (0.79x), but comparable to Max Healthcare (11.77x) and Narayana Hrudayalaya (10.15x). This premium P/BV multiple reflects market recognition of the company's strong ROE and growth trajectory, though it also amplifies downside risk if growth disappoints or margins compress.

On the income front, Global Health's dividend yield of 0.04% ranks amongst the lowest in the sector. The company paid a dividend of ₹0.50 per share with an ex-dividend date of August 22, 2025, translating to minimal income for investors. In contrast, Aster DM Healthcare offers 0.71% yield, Apollo Hospitals and Narayana Hrudayalaya provide 0.25% each, suggesting Global Health prioritises capital retention for growth over shareholder distributions.

Shareholding Dynamics: Institutional Confidence Building Gradually

The shareholding pattern reveals a stable promoter base and gradually increasing institutional participation. Promoter holding has remained steady at 33.01% in Q2 FY26, virtually unchanged from 33.04% in Q2 FY25. This consistency signals promoter confidence and commitment, with Dr. Naresh Trehan, the founder and renowned cardiovascular surgeon, maintaining his 33.01% stake. Importantly, there is zero promoter pledging, eliminating concerns about financial stress or forced selling.

Foreign institutional investors (FIIs) have marginally reduced their stake to 11.40% in Q2 FY26 from 11.54% in Q1 FY26, continuing a gradual declining trend from 12.47% in Q4 FY25. This 107-basis-point reduction over three quarters suggests some profit-booking by foreign investors, possibly driven by valuation concerns or portfolio rebalancing. With 203 FII holders, the stock maintains reasonable foreign institutional interest, though the declining trend warrants monitoring.

Conversely, mutual fund holdings have increased notably, rising to 11.83% in Q2 FY26 from 10.66% in Q1 FY26, marking a 117-basis-point sequential increase. This represents the strongest quarterly increase in mutual fund participation over the past year, with holdings expanding from 9.00% in Q4 FY25. The presence of 27 mutual fund schemes holding the stock indicates broad-based domestic institutional interest, with this increasing stake suggesting fund managers view the current valuation as offering long-term value despite near-term concerns.

The combined institutional holding (FII, mutual funds, insurance, and other DIIs) stands at 24.38%, demonstrating healthy institutional participation. However, the non-institutional shareholding of 42.61% remains substantial, indicating significant retail and high-net-worth individual interest. The reduction in non-institutional holding from 43.28% in Q1 FY26 to 42.61% in Q2 FY26 suggests some retail profit-booking, likely triggered by the stock's run-up earlier in the year.

Stock Performance: Momentum Stalls After Strong Run

Global Health's stock has delivered mixed returns across different timeframes, with strong long-term performance offset by recent weakness. The stock generated 15.83% returns over the past year, outperforming the Sensex's 4.62% gain by 11.21 percentage points. On a two-year basis, the outperformance is even more pronounced, with the stock delivering 51.10% returns against the Sensex's 28.14%, translating to an alpha of 22.96 percentage points.

However, the recent performance tells a different story. The stock has declined 7.29% over the past month, underperforming the Sensex's 1.57% gain by 8.86 percentage points. This weakness extends to the three-month period, with the stock down 5.23% against the Sensex's 3.22% gain, resulting in negative alpha of 8.45 percentage points. The one-week decline of 4.49% and one-day fall of 1.97% indicate accelerating downward momentum.

Trading at ₹1,255.00 as of November 7, 2025, the stock sits 13.80% below its 52-week high of ₹1,455.85 reached earlier in the year. On the positive side, it remains 26.12% above its 52-week low of ₹995.05, suggesting the stock has found support and hasn't entered deeply oversold territory. The stock trades below all major moving averages—5-day (₹1,300.38), 20-day (₹1,349.90), 50-day (₹1,356.01), 100-day (₹1,315.96), and 200-day (₹1,247.73)—indicating technical weakness across multiple timeframes.

The stock's beta of 1.20 classifies it as a high-beta security, meaning it tends to be 20% more volatile than the broader market. This higher volatility is reflected in the stock's 30.84% annualised volatility compared to the Sensex's 12.39%. Whilst this volatility creates opportunities for traders, it also amplifies risk for long-term investors, particularly at current valuation levels where downside protection is limited.

Technical Landscape: Sideways Consolidation Amid Mixed Signals

The technical picture for Global Health has deteriorated from "MILDLY BULLISH" to "SIDEWAYS" as of November 3, 2025, when the stock was trading at ₹1,275.75. This trend change reflects the stock's inability to sustain upward momentum and suggests a period of consolidation or potential further weakness. The weekly and monthly MACD indicators both show "MILDLY BEARISH" signals, indicating weakening momentum across multiple timeframes.

Bollinger Bands present conflicting signals, with the weekly timeframe showing "BEARISH" whilst the monthly remains "MILDLY BULLISH". This divergence suggests uncertainty about near-term direction, with the stock potentially range-bound between support at the 52-week low of ₹995.05 and resistance at the 20-day moving average of ₹1,349.90. The immediate resistance zone between ₹1,315-1,350 will be critical for the stock to reclaim bullish momentum.

The On-Balance Volume (OBV) indicator shows "MILDLY BEARISH" signals on the weekly timeframe but "BULLISH" on monthly, suggesting accumulation on longer timeframes despite recent distribution. Delivery volumes have shown interesting patterns, with one-month delivery volume increasing 12.02% compared to the previous month, and the most recent session showing 59.82% delivery against a five-day average of 71.98%. This elevated delivery percentage suggests genuine investor interest rather than speculative trading, though the recent decline indicates profit-booking pressure.

Investment Thesis: Quality Meets Valuation Reality

Global Health's investment case rests on four pillars, each contributing to the overall Mojo Score of 54 out of 100. The "GOOD" quality grade reflects the company's strong fundamentals: zero debt, consistent profitability, superior ROE of 15.90%, and healthy long-term growth with a five-year EBIT CAGR of 33.58%. These quality metrics justify investor interest and explain the stock's premium valuation relative to book value.

The "POSITIVE" financial trend designation stems from the company's recent performance, with H1 FY26 net profit of ₹317.45 crores growing 33.87% year-on-year. The quarterly revenue hitting an all-time high of ₹1,099.22 crores and operating profit reaching ₹246.93 crores demonstrate operational momentum. This positive trend provides confidence in the company's ability to deliver on growth expectations, though margin pressures warrant monitoring.

However, the "VERY EXPENSIVE" valuation grade represents the primary constraint on the investment thesis. With a P/E ratio of 59 times, P/BV of 9.96 times, and PEG ratio of 3.20, the stock offers limited margin of safety. The valuation implies expectations of sustained high growth and margin expansion, leaving little room for execution missteps or sector headwinds. This expensive valuation has persisted since January 2025, suggesting the market has fully priced in the company's growth story.

The "SIDEWAYS" technical trend adds a layer of uncertainty, indicating the stock lacks directional conviction. Trading below all major moving averages and exhibiting negative momentum on shorter timeframes suggests technical weakness that could persist until fundamental catalysts emerge or valuation becomes more attractive through either price correction or earnings growth.

Outlook: What Lies Ahead for Medanta

Global Health's forward trajectory hinges on its ability to sustain operational momentum whilst managing margin pressures and justifying its premium valuation. The company's guidance for FY26 will be critical, particularly regarding capacity expansion plans, margin improvement initiatives, and strategies to optimise employee cost growth. With only two quarters remaining in FY26, the company needs to demonstrate consistent execution to meet market expectations embedded in its elevated valuation.

The hospital sector in India continues to benefit from structural tailwinds: rising healthcare expenditure, increasing insurance penetration, growing preference for organised healthcare, and an ageing population requiring more medical services. Global Health, with its Medanta brand positioned in the premium segment and presence in key metropolitan areas, stands to benefit from these secular trends. However, competition is intensifying as peers expand aggressively, potentially pressuring both pricing power and market share.

The key monitoring points for investors include quarterly margin trends, employee cost management, capacity utilisation rates, and any announcements regarding expansion plans. The company's ability to maintain operating margins above 22% whilst growing revenue at double-digit rates will be crucial for sustaining investor confidence. Any guidance on return of capital to shareholders through increased dividends or buybacks could also serve as a positive catalyst, given the current negligible dividend yield.

From a valuation perspective, the stock needs either a significant price correction or sustained earnings growth to become attractive. A 15-20% price decline to the ₹1,000-1,050 range would bring the P/E ratio closer to 45-48 times, potentially offering better risk-reward. Alternatively, if the company can deliver net profit growth of 25-30% over the next two years whilst maintaining margins, the current valuation could be justified, though this scenario offers limited upside from current levels.